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ABSTRACT

Confocal Raman Mapping (CRM) is a powerful, label free, non-destructive tool,
enabling molecular characterisation of human skin with applications in the dermocosmetic field. Coupling CRM to multivariate analysis can be used to monitor the
penetration and permeation of Active Cosmetic Ingredients (ACI) after topical
application. It is presently illustrated how Multivariate Curve Resolution Alternating
Least Squares (MCR-ALS) can be applied to detect and semi-quantitatively describe
the diffusion profile of Delipidol®, a commercially available slimming ACI, from
Raman spectral maps. Although the analysis outcome can be critically dependent on the
a priori selection of the number of regression components, it is demonstrated that
profiling of the kinetics of diffusion into the skin can be established with or without
additionnal spectral equality constraints in the multivariate analysis, with similar
results. Ultimately, MCR-ALS, applied without spectral equality contraints, specifically
identifies the ACI as one of main spectral components enabling to investigate its
distribution and penetration into the stratum corneum and underlying epidermis layers.
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1 | INTRODUCTION
The dense corneocyte layers and lipid rich composition of
the Stratum Corneum (SC) of the skin ensure a particularly
effective defence against exogenous agents. It is well
accepted that the resulting barrier function can strongly
compromise the efficiency of Active Cosmetic Ingredients
(ACI) by limiting their penetration. However, many
commercialised ACI in skin products have cellular targets
located in deeper layers of the skin, below the SC. As a result,
evaluation of cosmetic products, i.e. biological testing, to
validate the diffusion of the ACI into the skin cannot be
circumvented. While chromatographic techniques can be
considered as gold standards [1], enabling determination of
the kinetics of penetration with high accuracy and sensitivity,
large amounts of solvents are used for such analysis, making
the method non eco-friendly (an increasing concern in the
cosmetic industry). Moreover, tape stripping protocols
employed for chromatographic analysis lead to lack of
accuracy at a sub-micrometric level, due the nature of the
mechanical separation of cell layers with adhesive films.
Over the last 30 years, Raman spectroscopy has gained
popularity in this specific field of application [2]. This nondestructive, label free and reagent (solvent) free technique
provides molecular fingerprints based on the intrinsic,
inelastic scattering of light, when the sample is illuminated
with a laser source without adding any tracer. Moreover,
coupling the molecular specificity of the analysis with the
micrometric spatial resolution offers a relevant platform for

evaluation of local diffusion and distribution of active
molecules [3]–[9].
However, bio-analytical applications of Raman spectroscopy,
along with Near Infrared (NIR) and Fourier Transform
Infrared (FT-IR) spectroscopy, are hampered by the
complexity of the spectral signatures originating from
combined contributions from all the chemical compounds in
the analysed area. Therefore, advanced data mining
protocols are usually necessary to extract and interpret the
spectral information inside the large data sets generated by
hyperspectral mapping, and pre-processing can also play a
key role in correcting or diminishing spectral variability
originating from several optical and instrumental effects [10].
Recently, the development of multivariate analysis (i.e.
chemometrics) has greatly contributed to increasing the
potential of spectroscopy mapping for tissue, cell, and
surface analysis of material but also in pharmaceutical and
cosmetic fields [3], [7], [19], [20], [11]–[18]. Principal
Components Analysis (PCA) and K-means clustering
methods are examples of descriptive unsupervised methods,
widely used to better understand the hyperspectral data [21].
The former, PCA, is often applied to reduce the number of
variables in a multidimensional data set and the analysis of
the identified principal components can provide some
information about the origin of the variability of the data.
The second approach, K-means clustering, is a method
commonly employed in spatial mapping applications, by
which regions of similar spectral profiles are associated. A
number of examples of applications of PCA and/or K-means
clustering to understand how skin components evolve under
specific conditions [11], [12] and to detect the presence of
exogenous molecules [7], [13] have been reported. Such
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methods are particularly interesting for interpretation of
large hyperspectral maps containing hundreds to thousands
of data points. However, they are unable to provide the
spectral signatures of specific biochemical components and
their respective abundance from data. Thus, to access the
distribution of specific chemicals, it is necessary to use more
elaborate unmixing methods. Decomposing each pixel of an
image in a combination of estimated constituent spectra,
according to their respective abundance, enables both
qualitative and quantitative characterisation. Therefore,
biomedical profiles of cells and tissues can be analysed to
access subtle changes linked to biological mechanisms or
pathological development [22], [23]. Among the available
unmixing approaches, Classic Least Squares (CLS) and
Independent Components Analysis (ICA) are methods
commonly employed in a wide range of industrial
applications, including monitoring the penetration of
molecules such as penetration enhancers, vitamins or other
active ingredients [3], [13]–[15], control of pharmaceutical
products or detection of counterfeit medicines [16], [17].
While CLS uses a collection of spectral references of all
components in the sample to estimate their respective
abundance, ICA only requires an estimation of the number
of components present to decompose them. Singular Value
Decomposition (SVD) is widely used to estimate this
parameter, while Durbin-Watson criterion and KMO index
are also regularly used [24], [25]. However, since ICA does
not impose a non-negativity constraint on the constituent
spectra, the biochemical interpretation of spectral
decomposition is more complicated.
A recent study has investigated the penetration of Delipidol®
through the skin by means of Non-negative Constrained
Least Squares (NCLS) applied to skin cross sections [26].
Reconstructed distribution maps and penetration profiles of
this molecule were estimated using a measured pure
spectrum of ACI. However, this method presents some
limitations as its performance relies on the availability of a
large number of spectra from control samples but also on the
feasibility of collecting highly reliable reference spectra
from pure compounds. The use of such a reference spectral
data base excludes the possibility of, for example, band shifts
due to molecular interactions.
In contrast, Multivariate Curve Resolution Alternating Least
Squares (MCR-ALS) regression analysis is an unmixing
method which can provide an accurate molecular
decomposition of the spectroscopic information contained in
the data set, while also dealing with such band shifts [27].
MCR-ALS has been applied to detect modification in
ingredients and their dosing in falsified medicine [16], [18]–
[20], [28]. The method has also been applied on FT-IR and
Raman data to study effects of pathology, anatomy,
environmental or genetic factors [27] and on Raman data
collected from plant cell walls to study the mechanical
stability of cells by changing their form, their thickness or
their composition [29]. The advantages of MCR-ALS [30]
over other multivariate approaches lies in the possibility to
add some constraints to the model, such as non-negativity or
equality constraints. The equality constraints can be a known
spectrum or/and concentration, while retaining a reduced
number of components. Additionally, the method does not

require large control data sets. Therefore, MCR-ALS is an
attractive alternative to most common methods proposed to
evaluate the efficiency and innocuity of cosmetic products,
starting with establishing their distribution profiles of the
ACI to study their kinetics of penetration in skin layers.
This work aims to evaluate the MCR-ALS algorithm for the
tracking of an ACI through the skin with Raman
spectroscopy. The investigation addresses whether an a
priori knowledge of the tracked molecule is necessary, and
thus whether forcing one spectral signature to be that of the
ACI signature changes the performance of the MCR-ALS
approach in its data decomposition and fitting.

2 | Experimental data set
The present work proposes to revisit and optimise the data
analysis of previously published material [26]. The initial
work was performed using NCLS and full details are
provided in reference. Briefly, Raman spectra were acquired
using a LabRam (Horiba Jobin-Yvon, Villeneuve-d'Ascq,
France). Samples of Punica granatum seed oil
hydroxyphenethyl esters, commercialised as Delipidol®,
were kindly provided by BioEurope Solabia, France Solabia
(Pantin, France). It is a patented formulation used as an anticellulite ACI. Ethanolic solution of 5% Delipidol® has been
topically applied for 1h, 2h and 3h onto human reconstructed
skin samples (Episkin®, Lyon, France). Raman maps were
collected from 20𝜇𝑚 thick cross-sections prepared using a
cryo-microtome and placed on Raman grade CaF2 substrates.
As mentioned in [26], ethanol is a solvent which can act as
penetration enhancer leading to superior diffusion of
Delipidol®. However, the aim of the experiment was to
construct a set of Raman images with noticeable variations
in the ACI concentrations to illustrate the application of
multivariate analysis, i.e MCR-ALS.

3 | Data processing and analysis
3.1 | Data pre-processing
All Raman spectra were subject to pre-processing, including
spectral denoising, baseline correction, followed by
normalisation. All pre-processing steps were performed in
MATLAB (R2017b).
3.1.1 | Spectral denoising

The spectra were first filtered with a PCA to remove the
noise [31]. PCA is a multivariate data analysis technique that
aims to summarise and simplify the information available
with as little information loss as possible. This simplification
consists of transforming the variables to ones uncorrelated
with each other. Once the uncorrelated principal components
have been selected, all data are projected onto them, to go
back to the original space. Hence, the noise is reduced. Note
that, in the spectroscopy field, it is common to reduce the
dimensionality of the spectral data set while preserving its
main features to make it possible to remove the noise [32],
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[33]. In this work, 1% of the number of spectral data was
used as the number of loadings for the data projection (more
details in Supplementary Materials FIGURE S1).
3.1.2 | Baseline Correction

During spectral acquisition, instrumental phenomena,
scattering or intrinsic fluorescence by certain molecules
under the excitation laser can introduce a background to
spectra. This baseline has to be corrected prior to data
analysis.
The Rubberband method is a well-established and previously
employed background correction algorithm [10], [34]–[37]
that was preferred in this study.
The Rubberband method estimates a piecewise polynomial
baseline. First, a set of supports points is determined, such
that the region below these points form a convex hull. Then,
a polynomial curve is estimated between each support point.
The polynomial order was set to 1 to avoid overcorrection of
spectra. Finally, the set of these estimated polynomials
compose the baseline and they are subtracted from the
spectra (FIGURE S2).
3.1.3 | Normalisation

The last step of the pre-processing corresponds to the data
normalisation. In this work, it was achieved by calculating
the ratio of spectra to their respective Euclidian norms.
3.2 | Data analysis
3.2.1 | MCR-ALS

Unmixing methods assume that the data matrix 𝐷, of size
𝑁 × 𝑁𝜆 where 𝑁 and 𝑁𝜆 are respectively the number of
pixels/spectra and Raman shifts, can be expressed as a linear
combination of pure constituent spectra, weighted by their
respective abundance (FIGURE 1). Mathematically, the
data 𝐷 are considered to be the product of a pure spectra
matrix 𝑆 𝑇 , composed of 𝐾 components, multiplied by the
matrix of relative concentration 𝐶 of these 𝐾 components in
each pixel, as following:
𝐷 = 𝐶𝑆 𝑇 + 𝐸

(1)

where 𝐸 is the residual matrix of the linear model (1).

FIGURE 1 – Linear mixing model

Furthermore, the MCR-ALS algorithm is a self-modelling
method. It resolves an optimisation problem through the
minimisation of the adjustment errors 𝐸 of the linear model.
The minimisation problem to be solved is expressed as:
min‖𝐷 − 𝐶𝑆 𝑇 ‖

(2)

Some constraints have been added to this optimisation
problem to respect some logical and chemical properties,
such as positivity of the estimated Raman spectra and their
relative concentrations. The non-negativity constraint on
spectra and relative concentration is introduced to the
minimisation problem, such that equation (1) becomes:
min ‖𝐷 − C𝑆 𝑇 ‖2

𝑆≥0,𝐶≥0

(3)

The minimisation problem (4) can be solved by different
algorithms. The MCR-ALS method is one of them and the
algorithm is designed to better fit the model to the data by
alternatively minimising residuals by least squares fitting,
according to the spectral matrix 𝑆 and to the associated
abundance matrix 𝐶 . Hence, the ALS aspect of the
implementation is expressed as:
𝐶 = 𝐷𝑆(𝑆 𝑇 𝑆)−1

(4)

𝑆 𝑇 = (𝐶 𝑇 𝐶)−1 𝐶 𝑇 𝐷

(5)

Ultimately, MCR-ALS relaxes the hypothesis of the
presence of pure components within the data and it assumes
that each pixel is a mixed signal (FIGURE 33).
Although the MCR-ALS algorithm aims at solving a global
minimisation problem, its initialisation can influence the
quality of the results. Therefore, it is preferable to use a
method such as SIMPLISMA (SIMPLe-to-use-InteractiveSelf-Modelling-Mixture-Analysis) [25] to provide initial
estimations of pure spectra, somehow close to the solution,
as a starting point, rather than a random approach that could
lead to unrealistic, outlier local minima [38].
SIMPLISMA estimates components of a mixture based on
the purity of spectra, which is defined as a modified
coefficient of variation:
𝑃𝑖 =

𝜎𝑖
𝜇𝑖 +𝛽

,

(6)

where 𝑃𝑖 is the purity coefficient for a given spectrum 𝑆𝑖 , 𝜎𝑖
the standard deviation, 𝜇𝑖 the mean spectrum and 𝛽 is a
coefficient offset between 1% and 5% of the mean. The
higher the coefficient, the more significant is the difference
to the mean, and therefore the component spectrum is
considered purer. Ultimately, the purest spectra are selected
based on the purity coefficient and also on their
orthogonality to each other.
Alternatively, if constituent spectra or/and relative
concentrations are known, the MCR-ALS method allows the
addition of constraints to impose this information onto the
constructed model. It consists of including the known spectra
into the spectral initialisation and setting the constraints on
the spectra and relative abundances in the respective
matrices 𝑆 and 𝐶 at each iteration. It should be noted, that, in
the absence of calibration, concentrations 𝐶 of constituents
are relative and their manifestation in the complex mixture is
dependent on the relative strength of the Raman scattering
cross sections, giving rise to the spectra 𝑆.
The MCR-ALS algorithm converges when the difference in
the model adjustment between two iterations is smaller than
a set threshold. MCR-ALS was applied using a multiset
approach, i.e. all images corresponding to 1h, 2h and 3h have
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been decomposed simultaneously to consider the kinetics of
Delipidol® penetration and increase the coherency of the
component extracted to more specifically reconstruct semiquantitative distribution maps.
It should be noted that the application of added constraints
such as non-negativity of spectra/abundances or
correspondence of one component with a reference spectrum
and the multiset approach promote singularity of the solution
and reduces its rotational ambiguity [39]. The MCR-Bands
algorithm described in [39] makes it possible to estimate the
rotational ambiguity of a solution. It consists of calculating
the relative signal contribution of every component of the
maximum and minimum band boundaries of the feasible
solutions and computes their differences. In the case where
there is no rotational ambiguity, the estimated maximum and
minimum band boundaries are close to the solution and the
computed difference is close to 0. In this work, MCR-ALS
and MCR-Bands algorithms have been applied using the
scripts from MCR-ALS GUI 2.0 software in Matlab [40].

determination, corresponds to the percentage of variations in
the spectral values of a component that can explain the
variations of the spectral values of another one. In other
words, this squared value corresponds to the recovery rate of
spectral bands between two components. In general, a
correlation coefficient superior to 0.9 in absolute value is
statistically considered as very high correlation, and
therefore such a correlation coefficient is considered to be
satisfactory, since more than 80% of variations of spectral
values will be interrelated [41].
- Histogram of residuals – A histogram is a graphical
representation to visualise the data set repartition. All ranges
of values are binned in classes, categorised according to the
number of values included in them. In other words, for this
work, all Raman intensities of mean model residuals are
organised in a series of intervals and the number of Raman
shifts having a Raman intensity included in each of them is
associated to them. The histogram shape provides some
information about the value distribution; in particular, a
Gaussian shape means that the residual noise is Gaussian.

3.2.2 | Number of components

Components are estimated Raman signatures used to
decompose each pixel of the image. Therefore, it is necessary
to set the number of components 𝐾 to be estimated in the
MCR-ALS computation. The parameter 𝐾 plays a critical
role in the decomposition of spectral maps, and the difficulty
with biological samples lies in the fact that this number is
unknown and difficult to estimate. Therefore, in order to
reduce the subjectivity, different mathematical approaches
are available to provide an estimation and guide the analysis.
The most commonly used is SVD. Two other criteria, the
Durbin-Watson criterion [25] and the Kaiser-Meyer-Olkin
Index (KMO) [24] have also been recently proposed.

4 | RESULTS AND DISCUSSION
4.1 | Spectral characterisation

All these criteria have been applied to the evaluation of
Raman maps of reconstructed skin samples exposed to
Delipidol®. While SVD is determined directly from the data
maps, the other two decision criteria are based on
SIMPLISMA outputs using a number of constituents ranging
from 1 to 20 . Further information can be found in
supplementary data.
3.2.3 | Analysis tools

Some statistic tools are needed to analyse the data
decomposition resulting from MCR-ALS. Correlation
coefficients are used to quantitatively compare spectral
components and highlight any possible matches to reference
spectra, while histograms of experimental residuals are used
to qualitatively evaluate the model fitting. They are
described below:
- Correlation coefficient – The correlation coefficient
measures the linear link between several variables. Two
components are positively and negatively correlated if their
correlation coefficient is respectively close to 1 and -1. Note
that a null value does not imply independence. Moreover, the
squared correlation coefficient, known as coefficient of

FIGURE 2 – Comparison of data mean spectrum at each exposure
time to the ACI with the reference spectrum of the ACI. A: control;
B: 1h; C: 2h; D: 3h and E: pure spectrum of Delipidol®. Data are
pre-processed with the Rubberband baseline.

Delipidol® has a characteristic Raman signature, with a
combination of intense specific peaks easily discernible and
weaker spectral bands partially overlapping with skin
features (FIGURE 2-E). As such, it is an interesting
candidate to evaluate unmixing approaches such as MCRALS. Spectral characterisation of Delipidol® is presented in
FIGURE 2-E, showing dominant spectral features at 1630
cm−1 (C═C stretching of the aromatic ring), 1254 cm−1
(C─C─C) and 1162 cm-1. Other weaker bands at 1441 cm-1,
1393cm-1, 1307 cm-1, 1251 cm-1, 1207 cm-1, 1076 cm-1, 991
cm-1, 969 cm-1, 865 cm-1, 843 cm-1 and 827 cm-1 can also be
observed.
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Mean spectra of Raman maps of control, 1h, 2h and 3h
exposure time are also illustrated in FIGURE 2 as an overall
initial comparison of spectra. For illustration purposes, mean
spectra presented have been obtained using the preprocessing strategy described above. In addition to those of
Delipidol®, Raman spectra collected from skin samples
exhibit a complex signature originating from combined
spectral features of physiological constituents. The amide I
band located at 1655 cm-1 indicates the skin is predominantly
composed of proteins such as keratin and other cellular
proteins [11]. Content may vary between the upper layers
corresponding to SC and other layers containing higher
proliferating cell density (e.g. basal layer). The position and
shape of the amide I band reflects changes in protein
composition but also in their conformation (secondary
structure) [42], and therefore can substantially vary across
the skin tissue section. Similarly, spectra contain a wealth of
information about lipids, contributing peaks identified at
1064 cm-1, 1129 cm-1 and 1297 cm-1 but also bands of DNA
and nucleic acids observed at 783 cm-1 (O–P–O), 813 cm-1
(O–P–O), 1086 cm-1 (O–P–O), 1252 cm-1 (guanine, cytosine),

1324 cm-1 (DNA) and 1340 cm-1 (DNA) [42]. However,
Delipidol® exhibits a characteristic Raman signature, with a
combination of intense specific peaks and weaker spectral
bands (FIGURE 2-E), which are easily discernible
superimposed on the spectrum of skin (FIGURE 2A,B,C,D) even in the mean spectra of the skin cross-section,
in which its localised contribution is naturally diluted. As a
result, each pixel of the image can be considered a complex
spectral mixture corresponding to the local biochemical
composition tempered with contributions from the ACI.
MCR-ALS applied to Raman maps is expected to deliver
more specific information about its distribution in the
different layers of the epidermis and consequently enable
construction of penetration profiles.
4.2 | MCR-ALS applied to ACI penetration study using
𝑲 = 𝟒 components with non-negativity constraint only
This section presents results of MCR-ALS applied only with
non-negativity constraints on spectra and relative

Spectral equality
constraint on the ACI

No spectral equality constraint
A
A1

A2

𝐾=4

C

B
B1

B2

𝐾=3

C1

C2

𝐾=8

D
D1

𝐾=4

D2

FIGURE 3 – MCR-ALS applied with only non-negativity constraints for 𝐾 = 4 (A) and 𝐾 = {3, 8} (B, C) and with an additional spectral
equality constraint on the ACI for 𝐾 = 4 (D) on pre-processed data; A1-B1-C1-D1: Spectra estimated with 𝐾 components initialized by
SIMPLISMA (offset for clarity); A2-B2-C2-D2: Reconstructed maps of Delipidol® in skin samples at 3h exposure time. Maps obtained using
estimating spectrum of ACI 𝑆1 (A2-B2-C2) or referential spectrum 𝑆1 (D2).
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𝑺𝟏

𝑺𝟐

𝑺𝟑

further employed to study the skin composition, and any
changes to it as a result of permeation of the ACI.
Moreover, the value of the differences of the relative
contributions of the 4 components of maximum and
minimum band boundaries estimated by application of the
MCR-Bands algorithm are respectively 1.16 × 10−3 ,
8.00 × 10−3 , −5.81 × 10−3 and −25.61 × 10−3 for 𝑆1 , 𝑆2 ,
𝑆3 and 𝑆4 , indicating that the rotational ambiguities are
negligible.
For each exposure time, penetration profiles of the ACI were
averaged over all samples (black curves in FIGURE 5)
displaying the permeation of Delipidol® into the SC for the
1h experiment, followed by progressive diffusion into deeper
layers of the epidermis after 2h and 3h exposure with a
concomitant increase in the outer layer (0-20 µm). It was
observed that average penetration profiles calculated using
the MCR-ALS applied with only non-negativity constraints
were close to the profiles obtained with a more constrained
approach such as NCLS [26] (FIGURE 5).
4.3 | Comparison of numbers of K parameters

FIGURE 4 – Reconstructed concentration distribution maps of 𝑆1 ,
𝑆2 and 𝑆3 in skin samples at 3h exposure time. They resulted from
MCR-ALS applied only with non-negativity constraints applied
with 𝐾 = 4.

concentrations and no ACI reference to guide the algorithm,
using 𝐾 = 4 components. The 4 estimated spectral
components are displayed in FIGURE 3-A, with
corresponding reconstructed distribution map for Delipidol®.
Results are illustrated with data subjected to Rubberband
baseline correction, derived from a multiset analysis,
including maps from 1h, 2h and 3h.
Spectral components are identified as 𝑆𝑖 for 𝑖 = 1, … , 4 ∈ ℕ
(FIGURE 3-A1) and their display order has been organised
so that they are more easily readable and comparable.
Compared to the reference spectrum of Delipidol®, spectral
component 𝑆1 exhibits strong similarities. Although a
shoulder at 1661 cm-1 suggests that a small residual feature
from the amide I band remains, the MCR-ALS applied with
only non-negativity constraints to spectra and abundances
was able to identify a spectral component with strong
similarities to the pure spectrum of the ACI studied
(correlation coefficient of 0.9746), highlighting that the
reference spectrum is not necessary to construct accurate
distribution maps. Distribution maps for components 𝑆2 , 𝑆3
and 𝑆4 obtained with 𝐾 = 4 are displayed in FIGURE 4.
These components exhibit features related to biochemical
constituents of the skin, such as lipids, proteins and nucleic
acids [11], consistent with those observed in the mean
spectra of FIGURE 2. Although it is not the subject of the
current study, the combination of Raman/MCR-ALS can be

The choice of 𝐾 = 4 in section 4.2.2 was rather subjective
and based on the similarity of 𝑆1 with the pure spectrum of
Delipidol®. However, the number of parameters chosen can
have an impact on the model performance.
It was anticipated that selecting a number of components for
the MCR-ALS applied to biological samples would be a
difficult task. Despite the existence of criteria to support the
analyst in this decision, the observation of SVD, DWC and
KMOI all suggested that a high number of components
would be necessary to encompass the entire biochemical
spectral variability (FIGURE S4). However, the purpose of
using advanced unmixing methods is to provide simplified
information about the distribution of Delipidol® which is
easily interpretable. Moreover, the criteria described took
into account the global information contained in the spectral
maps and they did not necessarily directly reflect the optimal
number of components to accurately and specifically detect
and localise the ACI onto chemical maps.
Plots obtained using SVD, DWC and KMOI are provided in
FIGURE S4. There is no unambiguous decision about the
optimal number of components to use for the spectra
decomposition. While SVD suggests 11 components would
be necessary to reach 95% of explained variance, DWC and
KMO tends to indicate that numbers between 4 and 8 could
capture the relevant spectral information contained in Raman
maps. Here are presented results from different sizes of the
spectral base (𝐾 = {3, 8}) to better understand the impact of
the parameter 𝐾 on the spectral unmixing and the model
fitting to the data. Hence, in order to evaluate the reliability
of MCR-ALS, the correlation coefficients have been
computed to estimate similarities between spectral
components and the reference spectrum of Delipidol ®, and
the interpretation of experimental residuals distribution by
means of histograms has been explored.
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𝐾=4

FIGURE 5 – Average penetration profiles of the Delipidol® for 1h, 2h and 3h of exposure time obtained by MCR-ALS applied with (red) versus
without (black) spectral equality constraints on the ACI and using K = 4. The average concentrations obtained by NCLS are illustrated by blue
points.

TABLE 1 – Correlation coefficients between estimated spectra 𝑆𝑖=1,…,𝐾 obtained by MCR-ALS applied with and without spectral equality
constraints on the ACI (𝐾 = {3, 4}) from data corrected with Rubberband method.
𝑲=𝟑
Spectral equality constraint
𝑺𝟏
No spectral
on the ACI
Delipidol®
equality constraint

𝑲=𝟒

𝑺𝟐

𝑺𝟑

𝑺𝟏
Delipidol®

𝑺𝟐

𝑺𝟑

𝑺𝟒

𝑺𝟏

0.9753

0.0512

0.3452

0.9746

0.3218

0.1393

0.1821

𝑺𝟐

0.0054

0.9994

0.4070

0.2518

0.9983

0.4214

0.3911

𝑺𝟑

0.2664

0.4425

0.9971

0.0681

0.4535

0.9979

0.7216

0.1110

0.4206

0.6790

0.9999

𝑺𝟒

TABLE 2 – Mean concentration of estimated ACI after 1h, 2h and 3h exposure time obtained by MCR-ALS applied with and without spectral
equality constraints on the ACI for 𝐾 = {3, 4} from data corrected with Rubberband method.
𝑲=𝟑

𝑲=𝟒

1h

2h

3h

1h

2h

3h

𝟎 − 𝟐𝟎𝝁𝒎

0.0635

0.5439

0.8050

0.0691

0.5364

0.8098

𝟐𝟎 − 𝟒𝟎𝝁𝒎

0.0012

0.1737

0.3477

0.0067

0.1753

0.3498

𝟒𝟎 − 𝟏𝟏𝟎𝝁𝒎 0.0058

0.0129

0.1532

0.0036

0.0115

0.1623

𝟎 − 𝟐𝟎𝝁𝒎
0.0534
Spectral
equality
𝟐𝟎 − 𝟒𝟎𝝁𝒎 0.0001
constraint on
the ACI
𝟒𝟎 − 𝟏𝟏𝟎𝝁𝒎 0.0016

0.5072

0.7643

0.0586

0.4995

0.7638

0.1553

0.3246

0.0013

0.1567

0.3247

0.0043

0.1343

0.0009

0.0049

0.1426

No spectral
equality
constraint
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Spectral components 𝑆𝑖 for 𝑖 = 1, … , 𝐾 ∈ ℕ with 𝐾 =
{3, 8} used for the MCR-ALS applied with only nonnegativity constraints are displayed in FIGURE 3-B1 and
FIGURE 3-C1, with corresponding reconstructed
distribution maps for Delipidol® in FIGURE 3-B2 and
FIGURE 3-C2. While distribution maps for 3h exposure
time appeared similar for 𝐾 = 3 and 𝐾 = 4, the outcome
with 𝐾 = 8 diverged for the first 2 models with clearly an
significantly lower abundance of Delipidol® in the 20 µm,
corresponding to the SC. Observations of spectral
components highlighted that, with 𝐾 = 8 , features of
Delipidol® at 1630 cm-1, 1442 cm-1, 1254 cm-1 and 1162 cm1
have been also found in 𝑆2 along with other skin features.
It is an example of over decomposition of the spectral
component of interest. While increasing the number of 𝐾
parameters should deliver overall a better fitting of the model,
presently the Delipidol® is no longer considered as single
pure component thus no interpretation of its distribution can
be made.
In comparison 𝑆1 components respectively calculated with
𝐾 = 3 and 𝐾 = 4 appears quite comparable. To estimate
the degree of similarity correlation coefficients of estimated
spectral components using 𝐾 = {3, 4} are presented in
TABLE 1 (table including 𝐾 = 8 is provided in

Supplementary Materials – TABLE S1). To be noted that 𝑆1
Delipidol® refers to the pure spectrum of the ACI. It is
observed that the correlation coefficients between the
spectral component of Delipidol® estimated from the
algorithm using only the non-negativity constraints and the
reference pure spectrum used (𝑆1 Delipidol®) are really high,
with respective values of 0.9753, 0.9746 for 𝐾 = 3 and 𝐾 =
4. Moreover, the estimated spectral component 𝑆2 and 𝑆3 for
𝐾 = 3 and 𝐾 = 4 do not match with the reference ACI
spectrum (correlation coefficients are respectively 0.0054,
0.2664 and 0.2518, 0.0681), suggesting the component
𝑆1 can be considered close to spectroscopically pure. In
contrast, 𝑆2 for 𝐾 = 8 has a relatively large correlation
coefficient of 0.8801 with the signature of Delipidol®
(Supplementary Materials – TABLE S1). As mentioned
above, this is a result of over-decomposition of the spectral
signatures resulting with presence of Delipidol® features in
multiple spectral components.
The study investigates the applicability of MCR-ALS to
construct distribution maps of the ACI as function of time. It
is expected that a gradient will be observed from the surface
of the skin (SC) towards deeper layers of the viable epidermis
(VE). Therefore, the comparison criteria between models
relies on the abundance of Delipidol® according to depth.

𝐾=3

𝐾=4
B

C

D

No spectral equality
constraint

Spectral equality
constraint on the ACI

A

FIGURE 6 – Histograms of mean residuals obtained by MCR-ALS applied with (A-B) and without (C-D) spectral equality constraints on the
ACI for 𝐾 = {3, 4} from data preprocessed with Rubberband baseline correction.
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Here, numerical values of the relative mean concentrations
for different depth ranges 0-20µm, 20-40µm and 40-110µm
for 𝐾 = {3, 4} have been calculated and are presented in
TABLE 2 (top part for analysis using only non-negativity
constraints). These values are also available for 𝐾 = 8 in
Supplementary Materials – TABLE S2. For 𝐾 = 3 and 𝐾 =
4 sensibly identical results are obtained for 1h, 2h and 3h.
For instance, after 3h of exposure, relative mean respective
concentrations are 0.8050 and 0.8098 in the 0-20 µm range.
Delipidol® reached inferior layers of the epidermis
progressively (40-110µm) and remained very concentrated
on the upper skin layer (0-20µm) after 3h.
FIGURE 6-C, D presents the distributions of model
residuals obtained by MCR-ALS using only non-negativity
constraints for 𝐾 = {3, 4} . The analysis of residuals can
bring additional insights about the impact of the number of
components 𝐾 used. While for 𝐾 = 4 residuals display a
nearly normal Gaussian distribution, which can correspond
with the remaining noise, the shape of the distribution of
residuals for 𝐾 = 3 is composed of two Gaussian, which
tends to indicate that not all spectral components have been
extracted from the data. The right-hand Gaussian part of the
distribution can be interpreted as residual noise, whereas the
left Gaussian indicates that some data variability is
mathematically not modelled. Increasing to 𝐾 = 4 restores
a unimodal Gaussian distribution, suggesting that no other
significant spectral components remain in the residuals.
Moreover, it is noted that the Gaussian distribution of the
residuals shifts to more centered values when 𝐾 is increased,
with a central tendency shifting from approximately
−0.85 × 10−4 to −0.25 × 10−4 and finally 0.05 × 10−4 ,
for respectively𝐾 = 3, 𝐾 = 4 and 𝐾 = 8. It suggests there
is a mathematical overexpression of some data variability in
the estimated model when K is too small.
MCR-ALS enables extraction of the spectrum of ACI from
the data set collected from the skin samples. Selecting too
few components leads to an unsatisfactory model in terms of
fitting errors. While the correlation coefficients (TABLE 1)
and relative mean concentrations (TABLE 2) indicate that
𝐾 = 3 and 𝐾 = 4 deliver sensibly similar results, the
experimental residuals suggest optimal fitting is obtained
with 4 components. Ultimately, 𝐾 = 4 is a good trade-off
between an acceptable fitting error and a coherent spectral
decomposition.
4.4 | Comparison of MCR-ALS applied with and without
spectral equality constraints on the ACI
Applying spectroscopic techniques for the analysis of
penetration and/or permeation profiles of ACIs in the
cosmetics field generally means the products themselves are
available, and that pure, or reference, spectra can be collected
before application onto the skin. In terms of application of
multivariate analysis protocols, these reference spectra can
be either employed to guide the analysis, by using them as
spectral equality constraints, or to validate the analysis. In
the following, the reference spectrum of Delipidol® is used

as a spectral equality constraint on the ACI to help MCRALS to estimate its relative concentrations.
As mentioned in [27], when comparing methods with and
without spectral equality constraints, it should be kept in
mind that inserting more constraints in the MCR-ALS
algorithm will naturally generally lead to a higher lack of fit
due to a set of conditions to be respected that diminishes the
flexibility of the model to find the optimal solution. Indeed,
as MCR-ALS adjusts the fitting of spectral components
through an iterative algorithm, using a fixed reference
spectrum of a component leads to fewer degrees of freedom
than an approach using only the non-negativity constraints.
This should be considered when analysing the residuals.
Adding some spectral equality constraints on the ACI can,
however, in some situations, reduce overfitting to spectra
that MCR-ALS would estimate as pure. but that could
actually have a mixed character. For the current application,
MCR-ALS was applied with 𝐾 = 4 components and with a
spectral equality constraint on the first component of the
model, 𝑆1 , fixed as a measured pure spectrum of Delipidol®,
while components 𝑆2 , 𝑆3 and 𝑆4 were calculated by the
algorithm. As expected, adding a spectral equality constraint
on 𝑆1 leads to higher residuals (FIGURE 6). The analysis
using a spectral equality constraint on the ACI indicates
distributions closer to normal, but the fitting error is tenfold
higher (10−3 ) compared to that not including it (10−4 ). The
lack of fit [27], [40] was also calculated. The estimated
model obtained by MCR-ALS applied without any spectral
equality constraint had a lack of fit of 5.21%. As expected,
adding a spectral equality constraint on the ACI in the
analysis increased this lack of fit by 2.17%.
Nevertheless, the estimated spectral components and the
reconstructed distribution maps for Delipidol® displayed in
FIGURE 3-D do not exhibit any noticeable difference
compared to the ones obtained by MCR-ALS applied
without spectral equality constraint (FIGURE 3-A). Indeed,
correlation coefficients for 𝑆2 , 𝑆3 and 𝑆4 between
approaches using spectral equality constraint on the ACI or
not were close to 1, with respective values of 0.9983, 0.9979
and 0.9999 (TABLE 1). The spectral components estimated
by applying a spectral equality constraint or not in the MCRALS analysis were found to be similar, for this application.
This is understandable, as the component S1 from the MCRALS applied without spectral equality constraint on ACI is
really close to the reference spectrum of Delipidol®, and thus
the mathematical decomposition for other components leads
to similar outcomes. This is confirmed by the trends in
penetration profiles which are comparable for both
approaches (FIGURE 5). Both average penetration profiles
present the same higher accumulation of Delipidol® in the SC
and progressive decrease in deeper layers (TABLE 2). Note
also that the kinetics of penetration described in this paper
are close to the ones previously obtained with an NCLS
approach [26] (FIGURE 5). However, comparison of
relative concentrations highlights a slightly lower estimated
abundance for the analysis using an additional spectral
equality constraint on the ACI. For example, in the SC (0-20
µm), when only non-negativity is applied to spectra and
relative concentrations, estimated abundances were 0.0691
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(1h), 0.5364 (2h) and 0.8098 (3h), while when a spectral
equality constraint on the ACI is added to the analysis, values
of 0.0586, 0.4995 and 0.7638 were found. Despite this slight
difference of relative abundances, the similarity of kinetics
of penetration for both approaches support the possibility of
using an MCR-ALS without spectral equality constraint on
the ACI for our application.
In the field of cosmetic research and development, Raman
spectroscopy can be a powerful tool to confirm a molecule is
able to diffuse trough the main barrier function of the SC and
reach deeper cellular targets, without the requirement to
access absolute concentrations. Images are a highly relevant
means of representation of results with high impact in the
industrial sector, especially in marketing, enabling
comparative studies between different conditions, which is
essential to support for example optimisation of formulations
for skin care products. Presently, for the case of Delipidol ®,
both approaches applied with and without spectral equality
constraint on ACI enable to reach converging results as
reconstructed images convey the same information
(FIGURE 2-A,B,C,D) and it may be considered that the
method addresses current needs for improved capabilities of
Raman spectroscopy for skin analysis.
Previously NCLS was explored to probe the distribution of
the ACI, rather than the specific skin components [26]. The
approach remain to model as closely as possible the
underlying skin contribution in spectra to more specifically
extract Delipidol® relative concentrations. MCR-ALS, both
approaches applying spectral equality constraint or not on
the ACI, appears easier to employ, due to the low
requirement for reference spectra to perform the analysis. In
comparison, methods such as NCLS are strongly limited by
their dependence on the degree of resemblance between the
pure spectra and the constituents found in the skin, making
the analysis less adaptive and thus prone to fitting errors.
MCR-ALS appears as potentially powerful alternative for
unmixing of spectral component and investigation of the
distribution of an ACI within skin cross sections. The
approach using a spectral equality constraint on the ACI is
quite relevant when a priori knowledge of the compound of
interest is available. Adding a constraint of fixing one of the
components with its pure spectrum enables to profile its
distribution within Raman maps and reduces the rotational
ambiguity of the results [39]. For the case of Delipidol®, it is
demonstrated that, despite a slight loss in the fitting quality,
the advantage lies in the absence of ambiguity in the results.
However, the use of a spectral equality constraint in MCRALS could also suffer from limitations in the case where the
ACI spectrum is changed because of, for example, the
influence of the local environment as it progresses through
the layers of the skin, crystallisation, accumulation in
reservoirs, or metabolisation, or indeed when the target of
the active is the molecular constituents of the skin itself. In
such cases, the outcome of analysis constrained or not in
spectral equality can be expected to diverge, and optimised

protocols for the more flexible MCR-ALS without
supplementary constraint could be more suited.

5 | CONCLUSION
Multivariate analysis provides promising unmixing methods
to understand and track the kinetics of diffusion of ACI in
skin samples from Raman data. In this work, results confirm
that Raman microspectroscopy coupled with MCR-ALS is a
powerful tool to detect and monitor an ACI penetration in the
upper layers of the skin. It is observed that for the case of
Delipidol® an a priori knowledge on the spectrum of ACI was
not necessary for the analysis when using the MCR-ALS
approach. The method applied without spectral equality
constraint on the ACI was able to estimate a characteristic
spectrum very close to that of ACI.
Ultimately, MCR-ALS decomposition provides similar
penetration profile estimations to the previously tested
NCLS, with the great advantage that it is a self modelling
approach that does not require complex and sometimes
unreliable large reference database of spectra from pure
components or an extended number of control data set
collected from control maps. In other words, the MCR-ALS
coupled to Raman mapping appears to be an efficient tool to
analyse and evaluate the effectiveness of ACI penetration
and could support further transfer of the technique into the
cosmetics industry.
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